Establishment of therapeutic platform using hematopoietic cytokines for cervical spinal cord injury without bony disorders

2019 Fiscal Year Final Research Report

• Project/Area Number: 17K10903
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Neurosurgery
• Research Institution: Yokohama City University
• Principal Investigator: Murata Hidetoshi 横浜市立大学, 医学部, 准教授 (40398524)
• Project Period (FY): 2017-04-01 – 2020-03-31
• Keywords: 脊髄症 / 頸髄損傷 / 造血サイトカイン / 顆粒球コロニー刺激因子 / エリスロポイエチン / 治療

Outline of Final Research Achievements

Recently, hematopoietic cytokines (granulocyte colony stimulating factor; G-CSF / erythropoietin; EPO) have been attracting attention for acute spinal cord injury. These cytokines are likely to be effective in clinically safe cervical spinal cord injury consisting of "compressive myelopathy" and "cervical trauma". Using the rat model of chronic spinal cord compression and cervical spinal cord injury without bony disorders, we aimed to clarify the effect of these hematopoietic cytokines to establish the best therapeutic platform.

Free Research Field

脳神経外科　脊髄外科

Academic Significance and Societal Importance of the Research Achievements

圧迫性脊髄症および脊髄損傷に対するG-CSFおよびEPOの効果は明らかとなり、いずれも国際誌 (SPINE2016, PLOS one 2019)で発表した。今後、造血サイトカインの全身性の影響を抑え、より効率的に効果を発揮できれば、臨床的に実用化が可能である。